


### **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims:**

Claims 1- 9 (Canceled).

Claim 10. (Previously presented): A method of treating a functional motility disorder of the viscera in a subject in need of such treatment, which comprises administering to said subject an effective amount of a compound of formula I



in free form or in the form of a pharmaceutically acceptable salt, wherein

R<sup>1</sup> is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, C<sub>1</sub>-C<sub>7</sub>-alkyl, trifluoromethyl, hydroxy and C<sub>1</sub>-C<sub>7</sub>-alkoxy;

R<sup>2</sup> is hydrogen or C<sub>1</sub>-C<sub>7</sub>-alkyl;


R<sup>3</sup> is hydrogen, C<sub>1</sub>-C<sub>7</sub>-alkyl or phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, C<sub>1</sub>-C<sub>7</sub>-alkyl, trifluoromethyl, hydroxy and C<sub>1</sub>-C<sub>7</sub>-alkoxy;

R<sup>4</sup> is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, C<sub>1</sub>-C<sub>7</sub>-alkyl, trifluoromethyl, hydroxy and C<sub>1</sub>-C<sub>7</sub>-alkoxy; or is naphthyl, 1H-indol-3-yl or 1-C<sub>1</sub>-C<sub>7</sub>-alkyl-indol-3-yl;

R<sup>5</sup> and R<sup>6</sup> are each independently of the other hydrogen or C<sub>1</sub>-C<sub>7</sub>-alkyl, at least one of R<sup>5</sup> and R<sup>6</sup> being hydrogen; and

R<sup>7</sup> is C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Claim 11. (Currently amended): A method according to claim 4~~10~~, in which the compound of formula I is of formula IA



in free form or in the form of a pharmaceutically acceptable salt,

where \* denotes the R configuration; and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are as defined in claim 4

R<sup>1</sup> is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, C<sub>1</sub>-C<sub>7</sub>-alkyl, trifluoromethyl, hydroxy and C<sub>1</sub>-C<sub>7</sub>-alkoxy;

R<sup>2</sup> is hydrogen or C<sub>1</sub>-C<sub>7</sub>-alkyl;

R<sup>3</sup> is hydrogen, C<sub>1</sub>-C<sub>7</sub>-alkyl or phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, C<sub>1</sub>-C<sub>7</sub>-alkyl, trifluoromethyl, hydroxy and C<sub>1</sub>-C<sub>7</sub>-alkoxy;

R<sup>4</sup> is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, C<sub>1</sub>-C<sub>7</sub>-alkyl, trifluoromethyl, hydroxy and C<sub>1</sub>-C<sub>7</sub>-alkoxy; or is naphthyl, 1H-indol-3-yl or 1-C<sub>1</sub>-C<sub>7</sub>-alkyl-indol-3-yl;

R<sup>5</sup> and R<sup>6</sup> are each independently of the other hydrogen or C<sub>1</sub>-C<sub>7</sub>-alkyl, at least one of R<sup>5</sup> and R<sup>6</sup> being hydrogen; and

R<sup>7</sup> is C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Claim 12. (Currently amended): A method according to claim 4~~10~~, in which

R<sup>1</sup> is phenyl, 3,5-bis(trifluoromethyl)-phenyl or 3,4,5-trimethoxyphenyl;

R<sup>2</sup> is hydrogen or C<sub>1</sub>-C<sub>7</sub>-alkyl;

R<sup>3</sup> is hydrogen or phenyl;

R<sup>4</sup> is phenyl, halo-phenyl, dihalo-phenyl, trihalo-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-C<sub>1</sub>-C<sub>7</sub>-alkyl-indol-3-yl;

R<sup>5</sup> and R<sup>6</sup> are each independently of the other hydrogen or C<sub>1</sub>-C<sub>7</sub>-alkyl, at least one of R<sup>5</sup> and R<sup>6</sup> being hydrogen; and

R<sup>7</sup> is C<sub>5</sub>-C<sub>7</sub>-cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Claim 13. (Currently amended): A method according to claim 2~~11~~, in which

R<sup>1</sup> is phenyl, 3,5-bis(trifluoromethyl)-phenyl or 3,4,5-trimethoxyphenyl;

R<sup>2</sup> is hydrogen or C<sub>1</sub>-C<sub>7</sub>-alkyl;

R<sup>3</sup> is hydrogen or phenyl;

R<sup>4</sup> is phenyl, halo-phenyl, dihalo-phenyl, trihalo-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-C<sub>1</sub>-C<sub>7</sub>-alkyl-indol-3-yl;

R<sup>5</sup> and R<sup>6</sup> are each independently of the other hydrogen or C<sub>1</sub>-C<sub>7</sub>-alkyl, at least one of R<sup>5</sup> and R<sup>6</sup> being hydrogen; and

R<sup>7</sup> is C<sub>5</sub>-C<sub>7</sub>cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Claim 14. (Currently amended): A method according to claim ~~4~~10, in which

R<sup>1</sup> is 3,5-bistrifluoromethyl-phenyl;

R<sup>2</sup> is hydrogen, methyl or ethyl;

R<sup>3</sup> is hydrogen or phenyl;

R<sup>4</sup> is phenyl, 4-chlorophenyl, 4-fluorophenyl, 3,4-dichloro-phenyl, 3,4-difluoro-phenyl, 3-fluoro-4-chloro-phenyl, 3,4,5-trifluoro-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-methyl-indol-3-yl;

R<sup>5</sup> and R<sup>6</sup> are each independently of the other hydrogen or methyl, at least one of R<sup>5</sup> and R<sup>6</sup> being hydrogen; and

R<sup>7</sup> is cyclohexyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Claim 15. (Currently amended): A method according to claim ~~2~~11, in which

R<sup>1</sup> is 3,5-bistrifluoromethyl-phenyl;

R<sup>2</sup> is hydrogen, methyl or ethyl;

R<sup>3</sup> is hydrogen or phenyl;

R<sup>4</sup> is phenyl, 4-chlorophenyl, 4-fluorophenyl, 3,4-dichloro-phenyl, 3,4-difluoro-phenyl, 3-fluoro-4-chloro-phenyl, 3,4,5-trifluoro-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-methyl-indol-3-yl;

R<sup>5</sup> and R<sup>6</sup> are each independently of the other hydrogen or methyl, at least one of R<sup>5</sup> and R<sup>6</sup> being hydrogen; and

R<sup>7</sup> is cyclohexyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Claim 16. (Currently amended): A method according to claim ~~4~~10, in which

R<sup>1</sup> is 3,5-bistrifluoromethyl-phenyl;

R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen or phenyl;

R<sup>4</sup> is phenyl, 4-chlorophenyl, 3,4-dichloro-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-methyl-indol-3-yl;

R<sup>5</sup> and R<sup>6</sup> are hydrogen; and

R<sup>7</sup> is cyclohexyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Claim 17. (Currently amended): A method according to claim ~~211~~, in which

R<sup>1</sup> is 3,5-bistrifluoromethyl-phenyl;

R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen or phenyl;

R<sup>4</sup> is phenyl, 4-chlorophenyl, 3,4-dichloro-phenyl, 2-naphthyl, 1H-indol-3-yl or 1-methyl-indol-3-yl;

R<sup>5</sup> and R<sup>6</sup> are hydrogen; and

R<sup>7</sup> is cyclohexyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.

Claim 18. (Currently amended): A method according to claim ~~410~~, in which the compound of formula I is selected from the group consisting of:

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-2-methyl-pent-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-2-methyl-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-2-methyl-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-2-methyl-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(naphth-2-yl)-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(naphth-2-yl)-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(naphth-2-yl)-2-methyl-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,4,5-trimethoxy-benzoyl)-amino]-5-(naphth-2-yl)-2-methyl-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(naphth-2-yl)-2-methyl-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(naphth-2-yl)-2-methyl-pent-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-but-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-but-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-difluorobenzyl)-but-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(4-chlorophenyl)-2-methyl-pent-2-enoic acid N-cyclohexylamide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(4-chlorophenyl)-2-methyl-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-2-methyl-but-2-enoic acid [(S)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-ethyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(4-chlorophenyl)-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(4-chlorophenyl)-3-methyl-pent-2-enoic acid N-cyclohexyl-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-3-methyl-but-2-enoic acid [(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)- and (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3-fluoro-4-chlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)- and (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-difluorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)- and (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dibromobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)- and (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4,5-trifluorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)- and (4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-fluorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,


(4R)- and (4S)-[N'-(3,5-bistrifluoromethyl-benzoyl)-N'-methyl-amino]-5,5-diphenyl-pent-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide,

(4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethylbenzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide,

(4R)-4-[N'-methyl-N'-(3,5-bistrifluoromethylbenzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide, and

(4S)-4-[N'-methyl-N'-(3,5-bistrifluoromethylbenzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(S)-epsilon-caprolactam-3-yl]-amide.

Claim 19. (Currently amended): A method according to claim 110, in which the compound of formula I is a compound of formula II



Claim 20. (Withdrawn): A method according to claim 1, in which the functional motility disorder is associated with visceral hypersensitivity or altered motor responses.

Claim 21. (Currently amended): A method according to claim 211, in which the functional motility disorder is a functional bowel disorder or a functional gastrointestinal disorder.

Claim 22. (Currently amended): A method according to claim ~~410~~, in which the functional motility disorder is irritable bowel syndrome ~~or functional dyspepsia~~.

Claim 23. (Currently amended): A method according to claim ~~211~~, in which the functional motility disorder is irritable bowel syndrome ~~or functional dyspepsia~~.

Claim 24. (Currently amended): A method according to claim 10, in which the functional motility disorder is irritable bowel syndrome ~~or functional dyspepsia~~.

Claim 25. (Currently amended): A method according to claim ~~410~~, in which the functional motility disorder is diarrhoea-predominant irritable bowel syndrome.

Claim 26. (Previously presented): A method according to claim 10, in which the functional motility disorder is diarrhoea-predominant irritable bowel syndrome.

Claim 27. (Currently amended): A method according to claim ~~410~~, wherein the effective amount of the compound of formula I is from 1 mg to 1000 mg.

Claim 28. (Currently amended): A method according to claim ~~410~~, wherein the effective amount of the compound of formula I is from 5 mg to 200 mg.

Claim 29. (Previously presented): A method according to claim 10, wherein the effective amount of the compound of formula IA is from 1 mg to 1000 mg.